BioOutsource (now part of Sartorius Stedim Biotech Group) is a leading provider of contract testing services to the global biopharmaceutical and biotechnology industries.
BioOutsource was founded in 2007 and was acquired by Sartorius Stedim Biotech in 2015. We are accredited for GMP, GLP and GCP and provide contract testing services to assess the quality and safety of biologic drugs and vaccines including:
- A range of off-the-shelf assays for biosimilar characterisation and comparability
- Biosafety testing of cell banks and bulk harvest as well as cell line stability and lot release
At BioOutsource we don’t just perform contract testing services; we are committed to delivering service excellence, with an in-house R&D department, we are constantly adding to our existing portfolio of services to address market demands. Our innovative approach and client management model ensures projects are managed efficiently, cost-effectively and delivered on-time.